Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Olema Pharmaceuticals (NASDAQ: OLMA), a clinical-stage biopharmaceutical company focused on targeted therapies for breast cancer, has granted stock options to four new employees. The grants total 104,400 shares of common stock with an exercise price of $5.29 per share, matching the company's last reported sale price on May 1, 2025.
The stock options, approved under Olema's 2022 Inducement Plan, will vest over four years, with 25% vesting on the first anniversary and the remaining portion vesting in 36 monthly installments. The options have a 10-year term and are contingent on continuous employment.
Olema Pharmaceuticals (NASDAQ: OLMA), un'azienda biofarmaceutica in fase clinica specializzata in terapie mirate per il cancro al seno, ha concesso opzioni azionarie a quattro nuovi dipendenti. Le concessioni ammontano a un totale di 104.400 azioni ordinarie con un prezzo di esercizio di 5,29 $ per azione, corrispondente all'ultimo prezzo di vendita riportato dall'azienda il 1° maggio 2025.
Le opzioni azionarie, approvate nell'ambito del Piano di Incentivazione 2022 di Olema, matureranno in un periodo di quattro anni, con il 25% delle azioni che maturerà al primo anniversario e la restante parte che maturerà in 36 rate mensili. Le opzioni hanno una durata di 10 anni e sono vincolate alla continuità dell'impiego.
Olema Pharmaceuticals (NASDAQ: OLMA), una empresa biofarmacéutica en etapa clínica enfocada en terapias dirigidas para el cáncer de mama, ha otorgado opciones sobre acciones a cuatro nuevos empleados. Las concesiones totalizan 104,400 acciones ordinarias con un precio de ejercicio de $5.29 por acción, igualando el último precio de venta reportado por la compañía el 1 de mayo de 2025.
Las opciones sobre acciones, aprobadas bajo el Plan de Incentivos 2022 de Olema, se consolidarán durante cuatro años, con un 25% consolidado en el primer aniversario y el resto en 36 cuotas mensuales. Las opciones tienen un plazo de 10 años y dependen del empleo continuo.
Olema Pharmaceuticals (NASDAQ: OLMA)는 유방암을 위한 표적 치료제에 중점을 둔 임상 단계의 바이오제약 회사로, 네 명의 신입 직원에게 주식 매수선택권을 부여했습니다. 총 104,400주의 보통주가 부여되었으며, 행사 가격은 주당 5.29달러로 2025년 5월 1일 회사가 마지막으로 보고한 매도 가격과 동일합니다.
Olema의 2022년 인센티브 플랜에 따라 승인된 이 주식 옵션은 4년에 걸쳐 베스팅되며, 첫 해 기념일에 25%가 베스팅되고 나머지는 36개월에 걸쳐 매월 분할 베스팅됩니다. 옵션의 유효 기간은 10년이며, 계속 고용 조건에 따라 발효됩니다.
Olema Pharmaceuticals (NASDAQ : OLMA), une entreprise biopharmaceutique en phase clinique spécialisée dans les thérapies ciblées pour le cancer du sein, a accordé des options d'achat d'actions à quatre nouveaux employés. Les attributions totalisent 104 400 actions ordinaires avec un prix d'exercice de 5,29 $ par action, correspondant au dernier prix de vente rapporté par la société le 1er mai 2025.
Les options d'achat d'actions, approuvées dans le cadre du Plan d'incitation 2022 d'Olema, seront acquises sur une période de quatre ans, avec 25 % acquis à la première anniversaire et le reste acquis en 36 versements mensuels. Les options ont une durée de 10 ans et sont conditionnées à une continuité d'emploi.
Olema Pharmaceuticals (NASDAQ: OLMA), ein biopharmazeutisches Unternehmen in der klinischen Phase, das sich auf gezielte Therapien gegen Brustkrebs spezialisiert hat, hat vier neuen Mitarbeitern Aktienoptionen gewährt. Die Zuteilungen umfassen insgesamt 104.400 Stammaktien mit einem Ausübungspreis von 5,29 $ pro Aktie, was dem zuletzt gemeldeten Verkaufspreis des Unternehmens am 1. Mai 2025 entspricht.
Die Aktienoptionen, die im Rahmen des Olema-Inducement-Plans 2022 genehmigt wurden, werden über vier Jahre unverfallbar, wobei 25 % am ersten Jahrestag und der Rest in 36 monatlichen Raten unverfallbar werden. Die Optionen haben eine Laufzeit von 10 Jahren und sind an eine fortlaufende Beschäftigung gebunden.
- None.
- None.
SAN FRANCISCO, May 02, 2025 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today announced that the Company granted stock options to four new employees to purchase an aggregate of 104,400 shares of the Company's common stock, effective as of May 1, 2025. These awards were approved by the Compensation Committee of Olema’s Board of Directors and granted under the Company's 2022 Inducement Plan as an inducement material to the new employees entering into employment with Olema, in accordance with Nasdaq Listing Rule 5635(c)(4).
The stock options vest over four years, with 25 percent vesting on the first anniversary of the vesting commencement date for such employee and the remainder vesting in 36 equal monthly installments over the following three years, subject to the employee being continuously employed by Olema as of such vesting dates. The stock options have a 10-year term and an exercise price of
Olema is providing this information in accordance with Nasdaq Listing Rule 5635(c)(4).
About Olema Oncology
Olema Oncology is a clinical-stage biopharmaceutical company committed to transforming the standard of care and improving outcomes for patients living with breast cancer and beyond. Olema is advancing a pipeline of novel therapies by leveraging our deep understanding of endocrine-driven cancers, nuclear receptors, and mechanisms of acquired resistance. Our lead product candidate, palazestrant (OP-1250), is a proprietary, orally available complete estrogen receptor (ER) antagonist (CERAN) and a selective ER degrader (SERD), currently in a Phase 3 clinical trial called OPERA-01. In addition, Olema is developing OP-3136, a potent lysine acetyltransferase 6 (KAT6) inhibitor, now in a Phase 1 clinical trial. Olema is headquartered in San Francisco and has operations in Cambridge, Massachusetts. For more information, please visit www.olema.com.
Media and Investor Relations Contact
Courtney O’Konek
Vice President, Corporate Communications
Olema Oncology
media@olema.com
FAQ
What stock options did Olema Pharmaceuticals (OLMA) grant to new employees in May 2025?
How does the vesting schedule work for OLMA's May 2025 employee stock options?
What is the exercise price for Olema's May 2025 inducement stock options?
Under which plan were OLMA's May 2025 employee stock options granted?
